Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

Anouk K. M. Claessens; Monique E. M. M. Bos; Marta Lopez-Yurda; Jeanette M. Bouma; Jeany M. Rademaker-Lakhai; Aafke H. Honkoop; Hiltje de Graaf; Edith van Druten; Laurence J. C. van Warmerdam; Maurice J. C. van der Sangen; Vivianne C. G. Tjan-Heijnen; Frans L. G. Erdkamp; Dutch Breast Canc Res Grp BOOG

doi:10.1007/s10549-018-4906-8

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

Anouk K. M. Claessens, Monique E. M. M. Bos, Marta Lopez-Yurda, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Hiltje de Graaf, Edith van Druten, Laurence J. C. van Warmerdam, Maurice J. C. van der Sangen, Vivianne C. G. Tjan-Heijnen, Frans L. G. Erdkamp, Dutch Breast Canc Res Grp BOOG

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	413-423
Number of pages	11
Journal	Breast Cancer Research and Treatment
Volume	172
Issue number	2
DOIs	https://doi.org/10.1007/s10549-018-4906-8
Publication status	Published - 1 Nov 2018

Keywords

Metastatic breast cancer
Chemotherapy
Scheduling
Duration
Paclitaxel
Bevacizumab
BEVACIZUMAB PLUS PACLITAXEL
PHASE-III TRIAL
LOCALLY RECURRENT
OPEN-LABEL
DOUBLE-BLIND
CHEMOTHERAPY
THERAPY
CAPECITABINE
SURVIVAL
EFFICACY

Access to Document

10.1007/s10549-018-4906-8

Cite this

Claessens, A. K. M., Bos, M. E. M. M., Lopez-Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., Honkoop, A. H., de Graaf, H., van Druten, E., van Warmerdam, L. J. C., van der Sangen, M. J. C., Tjan-Heijnen, V. C. G., Erdkamp, F. L. G., & Dutch Breast Canc Res Grp BOOG (2018). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Research and Treatment, 172(2), 413-423. https://doi.org/10.1007/s10549-018-4906-8

Claessens, Anouk K. M. ; Bos, Monique E. M. M. ; Lopez-Yurda, Marta ; Bouma, Jeanette M. ; Rademaker-Lakhai, Jeany M. ; Honkoop, Aafke H. ; de Graaf, Hiltje ; van Druten, Edith ; van Warmerdam, Laurence J. C. ; van der Sangen, Maurice J. C. ; Tjan-Heijnen, Vivianne C. G. ; Erdkamp, Frans L. G. ; Dutch Breast Canc Res Grp BOOG. / Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer : the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). In: Breast Cancer Research and Treatment. 2018 ; Vol. 172, No. 2. pp. 413-423.

@article{bc85bece73424ccaa39b4c08f2c72260,

title = "Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)",

keywords = "Metastatic breast cancer, Chemotherapy, Scheduling, Duration, Paclitaxel, Bevacizumab, BEVACIZUMAB PLUS PACLITAXEL, PHASE-III TRIAL, LOCALLY RECURRENT, OPEN-LABEL, DOUBLE-BLIND, CHEMOTHERAPY, THERAPY, CAPECITABINE, SURVIVAL, EFFICACY",

author = "Claessens, {Anouk K. M.} and Bos, {Monique E. M. M.} and Marta Lopez-Yurda and Bouma, {Jeanette M.} and Rademaker-Lakhai, {Jeany M.} and Honkoop, {Aafke H.} and {de Graaf}, Hiltje and {van Druten}, Edith and {van Warmerdam}, {Laurence J. C.} and {van der Sangen}, {Maurice J. C.} and Tjan-Heijnen, {Vivianne C. G.} and Erdkamp, {Frans L. G.} and {Dutch Breast Canc Res Grp BOOG}",

year = "2018",

month = nov,

day = "1",

doi = "10.1007/s10549-018-4906-8",

language = "English",

volume = "172",

pages = "413--423",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer, Cham",

number = "2",

}

Claessens, AKM, Bos, MEMM, Lopez-Yurda, M, Bouma, JM, Rademaker-Lakhai, JM, Honkoop, AH, de Graaf, H, van Druten, E, van Warmerdam, LJC, van der Sangen, MJC, Tjan-Heijnen, VCG, Erdkamp, FLG & Dutch Breast Canc Res Grp BOOG 2018, 'Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 413-423. https://doi.org/10.1007/s10549-018-4906-8

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer : the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). / Claessens, Anouk K. M.; Bos, Monique E. M. M.; Lopez-Yurda, Marta; Bouma, Jeanette M.; Rademaker-Lakhai, Jeany M.; Honkoop, Aafke H.; de Graaf, Hiltje; van Druten, Edith; van Warmerdam, Laurence J. C.; van der Sangen, Maurice J. C.; Tjan-Heijnen, Vivianne C. G.; Erdkamp, Frans L. G.; Dutch Breast Canc Res Grp BOOG.

In: Breast Cancer Research and Treatment, Vol. 172, No. 2, 01.11.2018, p. 413-423.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer

T2 - the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

AU - Claessens, Anouk K. M.

AU - Bos, Monique E. M. M.

AU - Lopez-Yurda, Marta

AU - Bouma, Jeanette M.

AU - Rademaker-Lakhai, Jeany M.

AU - Honkoop, Aafke H.

AU - de Graaf, Hiltje

AU - van Druten, Edith

AU - van Warmerdam, Laurence J. C.

AU - van der Sangen, Maurice J. C.

AU - Tjan-Heijnen, Vivianne C. G.

AU - Erdkamp, Frans L. G.

AU - Dutch Breast Canc Res Grp BOOG

PY - 2018/11/1

Y1 - 2018/11/1

KW - Metastatic breast cancer

KW - Chemotherapy

KW - Scheduling

KW - Duration

KW - Paclitaxel

KW - Bevacizumab

KW - BEVACIZUMAB PLUS PACLITAXEL

KW - PHASE-III TRIAL

KW - LOCALLY RECURRENT

KW - OPEN-LABEL

KW - DOUBLE-BLIND

KW - CHEMOTHERAPY

KW - THERAPY

KW - CAPECITABINE

KW - SURVIVAL

KW - EFFICACY

U2 - 10.1007/s10549-018-4906-8

DO - 10.1007/s10549-018-4906-8

M3 - Article

VL - 172

SP - 413

EP - 423

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -